What Is Mazdutide? GLP-1 and Glucagon Dual-Agonist Research

Most people following metabolic research are now familiar with GLP-1.

But an emerging area of research asks what happens when GLP-1 receptor activity is combined with glucagon receptor activity in the same molecule.

One of the most advanced examples is mazdutide.

Previously known by the development code IBI362, mazdutide is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics in collaboration with Eli Lilly.

Its mechanism makes it distinctly different from GLP-1-only compounds, GIP/GLP-1 dual agonists and triple agonists.

What Is Mazdutide?

Mazdutide is a peptide-based GLP-1 receptor and glucagon receptor dual agonist.

This means a single molecule has been engineered to interact with two separate receptor systems:

GLP-1 receptor

and

Glucagon receptor

That combination is important because the two pathways have different physiological functions.

Rather than simply increasing GLP-1 receptor activity, researchers are investigating what happens when GLP-1 and glucagon signalling are deliberately combined.

Why Target the Glucagon Receptor?

Glucagon is a peptide hormone produced primarily by pancreatic alpha cells.

It is widely recognised for its role in regulating glucose availability, particularly through effects on the liver.

But glucagon biology extends beyond glucose regulation.

Researchers have investigated its involvement in areas including energy expenditure, lipid metabolism and amino-acid metabolism.

That makes the glucagon receptor an interesting potential partner for other metabolic signalling pathways.

The challenge is achieving an appropriate balance between the different receptor activities.

Why Combine GLP-1 and Glucagon?

At first, combining the pathways can appear counterintuitive.

GLP-1 signalling is associated with glucose-dependent insulin secretion and regulation of glucagon release, while glucagon itself can increase hepatic glucose production.

But metabolic physiology isn’t governed by a single effect.

Researchers are interested in whether carefully balanced glucagon receptor activity could contribute useful metabolic effects when combined with GLP-1 receptor agonism.

This concept is sometimes described as a co-agonist approach.

Receptor Balance Matters

Mazdutide illustrates an increasingly important concept in peptide engineering:

which receptors a molecule targets is only part of the story.

Researchers also need to consider the relative activity at each receptor.

A molecule strongly activating one receptor and weakly activating another may behave differently from a molecule targeting the same receptors with a different activity profile.

This concept of receptor balance is becoming increasingly important as researchers develop dual and multi-receptor molecules.

Mazdutide vs GLP-1-Only Compounds

A conventional GLP-1 receptor agonist primarily focuses on one receptor pathway.

Mazdutide adds glucagon receptor agonism.

This means the research questions surrounding mazdutide extend beyond simply reproducing established GLP-1 pharmacology.

Scientists can investigate how the additional glucagon component changes metabolic responses.

This is what makes dual agonist research scientifically distinct from simply developing another GLP-1 compound.

Mazdutide vs GIP/GLP-1 Dual Agonism

Not all dual agonists target the same receptors.

This distinction can easily become lost when compounds are grouped together as “dual agonists.”

A GIP/GLP-1 dual agonist targets:

GIP + GLP-1

Mazdutide targets:

Glucagon + GLP-1

These aren’t interchangeable mechanisms.

The second receptor is completely different, meaning researchers are studying different biological interactions.

The term dual agonist therefore describes the number of receptor targets — not the specific mechanism.

From Oxyntomodulin to Engineered Co-Agonists

The idea of combining GLP-1 and glucagon signalling has roots in naturally occurring biology.

Oxyntomodulin is a peptide hormone capable of interacting with both GLP-1 and glucagon receptors.

Naturally occurring oxyntomodulin has characteristics that limit its usefulness as a long-acting pharmaceutical molecule.

Researchers have therefore investigated whether engineered peptides can reproduce aspects of this dual-receptor biology while providing more suitable pharmacological characteristics.

Mazdutide emerged from this broader area of research.

What Has Clinical Research Investigated?

Mazdutide has undergone a substantial clinical-development programme examining metabolic outcomes in adults with overweight, obesity and type 2 diabetes.

Researchers have studied measures including body weight, glucose-related outcomes, lipid markers and safety and tolerability.

As always, findings from individual trials need to be interpreted according to their specific population, duration, design and endpoints.

They shouldn’t automatically be compared numerically with unrelated trials involving different compounds.

A Significant Regulatory Milestone

Mazdutide is particularly notable because its development has progressed beyond the purely experimental early stages.

In 2025, China’s National Medical Products Administration approved mazdutide for chronic weight management in adults with obesity or overweight who met specified criteria.

This represented an important milestone for the GLP-1/glucagon dual-agonist approach.

Further research and regulatory development continue, and regulatory status can differ significantly between countries.

Approval in one jurisdiction doesn’t mean a medicine is approved elsewhere.

Why Glucagon Research Is Expanding

Glucagon was traditionally discussed primarily in relation to blood-glucose regulation.

Modern metabolic research has expanded that view.

Researchers are increasingly studying glucagon signalling in relation to:

• energy metabolism
• hepatic metabolism
• lipid regulation
• amino-acid metabolism
• interactions with other metabolic hormones

This broader understanding has helped make the glucagon receptor an increasingly important target in multi-receptor drug development.

Dual Agonists Are Not All the Same

Mazdutide provides an important lesson for interpreting modern peptide research.

Labels such as single agonist, dual agonist and triple agonist are useful, but they don’t tell the whole story.

Two dual agonists can target completely different receptor combinations.

Even compounds targeting the same receptors may differ in their molecular structure, receptor potency, pharmacokinetics and signalling characteristics.

Understanding the underlying biology is therefore more useful than simply counting receptor targets.

Why Mazdutide Is Important to Research

Mazdutide represents a distinct branch of modern metabolic science.

Rather than focusing on GLP-1 alone or pairing GLP-1 with GIP, it investigates the relationship between GLP-1 and glucagon signalling.

That provides researchers with another way to examine how multiple metabolic systems can be engineered into a single molecule.

Its development also demonstrates how research concepts that once appeared experimental can progress into late-stage clinical programmes and, in some jurisdictions, regulatory approval.

As scientists continue refining receptor balance and molecular design, GLP-1/glucagon co-agonism is likely to remain an important area of metabolic research.

Research Notice: Regulatory status varies by country. Mazdutide has received regulatory approval for specified indications in China but is not universally approved. This article is provided for scientific and educational information and does not provide medical advice, treatment recommendations or dosing guidance.